BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 215 filers reported holding BRIDGEBIO PHARMA INC in Q3 2021. The put-call ratio across all filers is 1.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $912,402 | -71.3% | 34,600 | -81.3% | 0.01% | -66.7% |
| Q2 2023 | $3,183,084 | -12.2% | 185,063 | -15.4% | 0.02% | -4.5% |
| Q1 2023 | $3,625,151 | +6769.8% | 218,646 | +3057.3% | 0.02% | – |
| Q4 2022 | $52,769 | -98.8% | 6,925 | -98.5% | 0.00% | -100.0% |
| Q3 2022 | $4,562,000 | +108.5% | 458,936 | +90.4% | 0.03% | +100.0% |
| Q2 2022 | $2,188,000 | -12.6% | 240,996 | -2.3% | 0.01% | -38.1% |
| Q1 2022 | $2,504,000 | +137.1% | 246,731 | +289.8% | 0.02% | +110.0% |
| Q4 2021 | $1,056,000 | +93.8% | 63,292 | +443.9% | 0.01% | +42.9% |
| Q3 2021 | $545,000 | +137.0% | 11,636 | +211.3% | 0.01% | +133.3% |
| Q1 2021 | $230,000 | -59.2% | 3,738 | -52.8% | 0.00% | -62.5% |
| Q4 2020 | $564,000 | -47.8% | 7,926 | -72.5% | 0.01% | -50.0% |
| Q3 2020 | $1,081,000 | – | 28,801 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |